TURKish Acute Myocardial Infarction Registry

Acute Myocardial Infarction Clinical Trial

— TURKMI  

Official title:

TURKish Acute Myocardial Infarction Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04241770
• Other study ID #: TURKMI Study
• Status: Recruiting
• Start date: November 1, 2018
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2020
• Source: Turkish Society of Cardiology
• Contact: MERAL KAYIKCIOGLU, Prof
• Phone: +905324123489
• Email: meral.kayikcioglu[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.

Description:

Background: There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.

Methods: TURKMI study, as a nation-wide registry, will be conducted in 50 percutaneous coronary intervention -capable centres selected from each EuroStat NUTS region in Turkey according to their population sampling weight, prioritizing the volume of hospital in each region. All consecutive patients with acute MI admitted to the coronary care units within the 48 hours of symptom onset will be prospectively enrolled during a predefined 2-week period.

The first step of the study has cross-sectional design in which baseline information such as symptoms, risk factors, time periods at each step from symptom onset to revascularization, way of arrival to hospital, biochemical analysis and in-hospital management and outcome will be assessed. The second step has a cohort characteristics in which enrolled patients will be followed-up up to 2 years. Follow-up visits will be conducted at 1st, 6th, 12th and 24th months, and predictors and risk of cardiovascular events, and implementation of guidelines will be assessed as secondary outcomes.

Conclusion: The national TURKMI registry is expected to provide important information to improve the national policy of the diagnosis, management and outcomes of MI in Turkey

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1930
• Est. completion date: December 31, 2023
• Est. primary completion date: December 1, 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. having hospitalized within 48 hours of onset of symptoms of the index event

2. had a final (discharge) diagnosis of acute MI either [ST elevation MI (STEMI) or non ST elevation (NSTEMI)] with positive troponin levels, and

3. having signed an Informed Consent. To facilitate consecutive enrolment, all patients hospitalized at each participating site with acute MI will be recruited consecutively during the same 2 consecutive weeks (15 days).

Exclusion Criteria:

1. Patients unwilling or unable to consent will be excluded.

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
Turkey	Meral Kayikcioglu	Izmir

Sponsors (2)

Lead Sponsor	Collaborator
Turkish Society of Cardiology	AstraZeneca

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants died	all cause of death including cardiovascular death	from enrollment till to 2 years follow up
Secondary	Number of participants developed cardiovascular morbidity	non-fatal MI, stroke, coronary or peripheral revascularization, emergency department visit due to chest pain or dyspnea, hospitalization for heart failure will be assessed at 1st month and then at every 6 month intervals until the second year.	from enrollment till to 2 years follow up